Table 6.
Phase 1 Multiple-Dose Studies [100] | ||
---|---|---|
ALT | Maraviroc (n = 272) | Placebo (n = 42) |
>2 to ≤ 5× ULN | 8 (2.9%) | 0 |
>5× ULN | 1 (0.4%) | 0 |
Bilirubin—Total | (n = 272) | (n = 41) |
>1.25 to ≤ 2.5× ULN | 3 (1.1%) | 0 |
>2.5× ULN | 0 | 0 |
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; ULN, upper limit of normal.